Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Revenue projections:

Revenue projections for BIOCON
Revenue projections for BIOCON

Biocon Limited's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 0.00000
forwardPE 42.04965
debtToEquity 62.76500
earningsGrowth -0.96200
revenueGrowth -0.03300
grossMargins 0.61127
operatingMargins 0.08541
trailingEps 6.71000
forwardEps 9.92000

BIOCON's low earnings and revenue growth suggest shrinking profits are likely. This could reflect broader financial struggles, signaling that the company might face difficulties in sustaining its profitability.
BIOCON's negative gross and operating margins suggest that the company is currently unprofitable, both in terms of production and overall operations. This could reflect rising costs or declining revenues, posing challenges for future profitability.
BIOCON's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights BIOCON's potential for increased earnings and a stronger financial performance in the upcoming year.

Price projections:

Price projections for BIOCON
Price projections for BIOCON

BIOCON's price projections have gradually increased over time, indicating that analysts are becoming more optimistic about the company's prospects. This suggests confidence in BIOCON's ability to achieve future growth.

Insider Transactions:

Insider Transactions for BIOCON
Insider Transactions for BIOCON


14 BIOCON transactions were recorded, when the market price was 275.38571384974887.There were no sell transactions recorded during the period under consideration.More buys than sells near the current price levels of Biocon Limited might signal a favorable outlook for the stock. Investors seem to be showing confidence by purchasing more, potentially expecting positive future performance.

Recommendation changes over time:

Recommendations trend for BIOCON
Recommendations trend for BIOCON


With analysts showing a buy bias for BIOCON, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning BIOCON as a safe and profitable place for investors to allocate their funds and seek growth.